GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rank in Stocks
#3636
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Share Price
$27.54
Last synced: 2026-10-19
Market Cap
$4.67B
Change (1 day)
-2.73%
Change (1 year)
-11.86%
Country
IN
Trade GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Category
Healthcare
Number of shares outstanding for GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Number of shares outstanding as of June 2026: 169.41M
According to GlaxoSmithKline Pharmaceuticals Limited latest financial reports and stock price the company's current number of shares outstanding is 169.41M. At the end of March 2024 the company had 169.41M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for GlaxoSmithKline Pharmaceuticals Limited (GLAXO) from 2004 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 169.41M | 0.00% |
| 2025 | 169.41M | 0.00% |
| 2024 | 169.41M | -0.50% |
| 2023 | 170.26M | -4.88% |
| 2022 | 178.98M | 5.65% |
| 2021 | 169.41M | 0.00% |
| 2020 | 169.41M | 0.00% |
| 2019 | 169.41M | 0.00% |
| 2018 | 169.41M | 0.00% |
| 2017 | 169.41M | 0.00% |
| 2016 | 169.41M | 0.00% |
| 2015 | 169.41M | 0.00% |
| 2013 | 169.41M | 0.00% |
| 2012 | 169.41M | 0.00% |
| 2011 | 169.41M | 0.00% |
| 2010 | 169.41M | 0.00% |
| 2009 | 169.41M | 0.00% |
| 2008 | 169.41M | 0.00% |
| 2007 | 169.41M | 0.00% |
| 2006 | 169.41M | -1.29% |
| 2005 | 171.62M | -1.73% |
| 2004 | 174.65M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 892.40M | 426.78% |
US
|
|
| 2.45B | 1,344.78% |
US
|
|
| 1.77B | 945.41% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 369.88% |
CH
|
